A clinicopathological cohort study of liver pathology in 301 patients with human immunodeficiency virus/acquired immune deficiency syndrome

Hepatology

Volumn 61, Issue 5, 2015, Pages 1721-1729

  Sonderup, Mark W ^a   Wainwright, Helen ^a   Hall, Pauline ^a,b   Hairwadzi, Henry ^a   Spearman, C Wendy N ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; COTRIMOXAZOLE; EFAVIRENZ; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE DISTRIBUTION; AIDS PATIENT; ARTICLE; DEMOGRAPHY; DRUG INDUCED DISEASE; FATTY LIVER; FEMALE; GRANULOMATOUS INFLAMMATION; HEPATITIS; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LIVER BIOPSY; LIVER DISEASE; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; NONALCOHOLIC FATTY LIVER; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; TOXIC HEPATITIS; TUBERCULOSIS; ACQUIRED IMMUNODEFICIENCY SYNDROME; COHORT ANALYSIS; COMPLICATION; DRUG-INDUCED LIVER INJURY; HIV INFECTIONS; LIVER DISEASES; PATHOLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DRUG-INDUCED LIVER INJURY; FEMALE; HIV INFECTIONS; HUMANS; LIVER DISEASES; MALE;

EID: 84928139654     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27710     Document Type: Article

References (50)

1. Joint United Nations Programme on HIV/AIDS. 2012 Global report: UNAIDS report on the global AIDS epidemic; November 2012. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_with_annexes_en.pdf.
2. Shisana O, Rehle T, Simbayi LC, Zuma K, Jooste S, Zungu N, et al. South African National HIV Prevalence, Incidence and Behaviour Survey, 2012. Cape Town, South Africa: HSRC Press; 2014. http://www.hsrc.ac.za/uploads/pageContent/4565/SABSSM%20IV%20LEO%20final.pdf.
3. WHO Global Tuberculosis Report 2014. http://www.who.int/tb/publications/global_report/en/.
4. Shisana O. HIV/AIDS in South Africa: at last the glass is half full. Human Sciences Research Council; 2013. http://www.hsrc.ac.za/en/media-briefs/hiv-aids-stis-and-tb/plenary-session-3-20-june-2013-hiv-aids-in-south-africa-at-last-the-glass-is-half-full#sthash.2JYWOdSI.dpuf.
5. Soriano V, Barreiro P, Sherman KE. The changing epidemiology of liver disease in HIV patients. AIDS Rev 2013;15:25-31.
6. Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet 2011;377:1198-1209.
7. Data Collection on Adverse Events of Anti-HIV Drugs Study Group. Liver-related deaths in persons infected with the HIV: the D:A:D study. Arch Intern Med 2006;166:1632-1641.
8. Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010;24:1537-1548.
9. Schneiderman DJ, Arenson DM, Cello JP, Margaretten W, Weber TE. Hepatic disease in patients with the AIDS. Hepatology 1987;7:925-930.
10. Lebovics E, Thung SN, Schaffner F, Radensky PW. The liver in the acquired immunodeficiency syndrome: a clinical and histologic study. Hepatology 1985;5:293-298.
11. Poles MA, Dieterich DT, Schwarz ED, Weinshel EH. Liver biopsy findings in 501 patients infected with HIV. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:170-177.
12. Piratvisuth T, Siripaitoon P, Sriplug H, Ovartlarnporn B. Findings and benefit of liver biopsies in 46 patients infected with human immunodeficiency virus. J Gastroenterol Hepatol 1999;14:146-149.
13. Lizardi-Cervera J, Soto Ramirez LE, Poo JL, Uribe M. Hepatobiliary diseases in patients with HIV treated with non-HAART: frequency and clinical manifestations. Ann Hepatol 2005;4:188-191.
14. Echejoh GO, Mandong BM, Tanko MN. Hepatic histopathological findings in HIV patients at postmortem in Jos University hospital, Nigeria. Trop Doct 2006;36:228-231.
15. Wong EB, Omar T, Setlhako GJ, Osih R, Feldman C. Causes of death on ART: a post-mortem study from South Africa. PLoS One;7:e47542.
16. Kovari H, Ledergerber B, Battegay M, Rauch A, Hirschel B, Foguena AK, et al. Incidence and risk factors for chronic elevation of ALT levels in HIV-infected persons without hepatitis B or C co-infection. Clin Infect Dis 2010;50:502-511.
17. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80.
18. Soriano V, Puoti M, Garcia-Gasco P, Rockstroh JK, Benhamou Y, McGovern B. Antiretroviral drugs and liver injury. AIDS 2008;22:1-13.
19. Smilack JD. Trimethoprim-sulfamethoxazole. Mayo Clin Proc 1999;74:730-734.
20. World Health Organization. Interim WHO clinical staging of HIV/AIDS and HIV/AIDS Case Definitions for Surveillance; 2005. http://www.who.int/hiv/pub/guidelines/clinicalstaging.pdf.
21. AIDS Clinical Trials Group. Grading severity of adult adverse experiences. Division of AIDS, NIAID, Rockville, MD; 1996.
22. Shishana O, Rehle T, Simbayi LC. South African National HIV Prevalence, Incidence, Behaviour and Communication Survey 2008: A Turning Tide Among Teenagers? Cape Town, South Africa: HSRC Press; 2009. http://www.hsrcpress.ac.za/product.php?productid=2264&cat=1&page=3.
23. Malaza A, Mossong J, Barnighausen T. Population-based CD4 counts in a rural area in South Africa with high HIV prevalence and high antiretroviral treatment coverage. PLoS One 2013;8:e70126.
24. Mayosi BM, Lawn JE, van Niekerk A, Bradshaw D, Abdool Karim SS, Coovadia HM. Health in South Africa: changes and challenges since 2009. Lancet 2012;380:2029-2043.
25. Jain MK. Drug-induced liver injury associated with HIV medications. Clin Liver Dis 2007;11:615-639.
26. Schutz C, Ismail Z, Proxenos CJ, Marais S, Burton R, Maartens G, et al. Burden of antituberculosis and antiretroviral DILI at a secondary hospital in South Africa. S Afr Med J 2012;102:506-511.
27. Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007;21:1301-1308.
28. Bongiovanni M, Tordato F. Steatohepatitis in HIV-infected subjects: pathogenesis, clinical impact and implications in clinical management. Curr HIV Res 2007;5:490-498.
29. Thiim M, Friedman LS. Hepatotoxicity of antibiotics and antifungals. Clin Liver Dis 2003;7:381-399, vi-vii.
30. Dieterich DT, Robinson PA, Love J, Stern JO. DILI associated with the use of non-nucleoside reverse-transcriptase inhibitors. Clin Infect Dis 2004;38(Suppl. 2):S80-S89.
31. Hoofnagle JH, Navarro VJ. Drug-induced liver injury: Icelandic lessons. Gastroenterology 2013;144:1335-1336.
32. Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984;100:495-499.
33. Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993;328:1670-1674.
34. Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005;191:825-829.
35. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002;35:182-189.
36. Mugusi S, Ngaimisi E, Janabi M, Minzi O, Bakari M, Riedel K-D, et al. Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania. PLoS One 2012;7:e40180.
37. Nunez M, Soriano V. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Drug Saf 2005;28:53-66.
38. Benhamou Y. Hepatitis B in the HIV-coinfected patient. J Acquir Immune Defic Syndr 2007;45(Suppl. 2):S57-S65; discussion S66-57.
39. Tucker TJ, Kirsch RE, Louw SJ, Isaacs S, Kannemeyer J, Robson SC. Hepatitis E in South Africa: evidence for sporadic spread and increased seroprevalence in rural areas. J Med Virol 1996;50(2):117-119.
40. Lanjewar DN, Rao RJ, Kulkarni SB, Hira SK. Hepatic pathology in AIDS: a pathological study from Mumbai, India. HIV Med 2004;5:253-257.
41. Holmes CB, Wood R, Badri M, Zilber S, Wang B, Maartens G, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 2006;42:464-469.
42. Hill AR, Premkumar S, Brustein S, Vaidya K, Powell S, Li PW, et al. Disseminated tuberculosis in the AIDS era. Am Rev Respir Dis 1991;144:1164-1170.
43. Aaron L, Saadoun D, Calatroni I, Launay O, Mémain N, Vincent V, et al. Tuberculosis in HIV-infected patients: a comprehensive review. Clin Microbiol Infect 2004;10:388-398.
44. Abdool-Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010;362:697-706.
45. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008;8:516-523.
46. Housset C, Pol S, Carnot F, Dubois F, Nalpas B, Housset B, et al. Interactions between HIV-1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus. Hepatology 1992;15:578-583.
47. Xiao SY, Lu L, Wang HL. Fibrosing cholestatic hepatitis: clinicopathologic spectrum, diagnosis and pathogenesis. Int J Clin Exp Pathol 2008;1:396-402.
48. Vallet-Pichard A, Mallet V, Pol S. Nonalcoholic fatty liver disease and HIV infection. Semin Liver Dis 2012;32:158-166.
49. Akhtar MA, Mathieson K, Arey B, Post J, Prevette R, Hillier A, et al. Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV without viral hepatitis. Eur J Gastroenterol Hepatol 2008;20:1194-1204.
50. Turlin B, Deugnier Y. Evaluation and interpretation of iron in the liver. Semin Diagn Pathol 1998;15:237-245.